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ABSTRACT
Objective: To define the relationship between intravesical prostatic protrusion (IPP), prostate specific antigen (PSA), and 
prostate volume (PV), and to determine which one is the best predictor of bladder outlet obstruction (BOO) due to benign 
prostatic enlargement. Material & method: 95 male patients > 40 years old presenting with LUTS and BPH, between 
January until July 2012. They were evaluated with digital rectal examination (DRE), International Prostate Symptoms 
Score (IPSS), total PSA serum, uroflowmetry, post-void residual urine measurement, IPP and PV using transabdominal 
ultrasound. Statistical analysis included Chi-square and Spearman's Rank correlation test. Receiver Operator 
Characteristic (ROC) curves were used to evaluate the correlation of PSA, PV, and IPP with BOO. Results: Mean PSA was 
significantly higher in obstructed patients (8.6 ng/mL; 0.76-130) compared to non-obstructed patients (6.44 ng/mL; 1.0-
40.6). Mean PV was significantly larger in obstructed patients (50.33 mL ± 24.34) compared to non-obstructed patients 
(45.39 mL ± 23.43). Mean IPP was significantly greater in obstructed patients (7.29 ± 2.78) compared to non-obstructed 
patients (6.59 ± 2.93). The Spearman rho correlation coefficients were 0.617, 0.721, and 0.797, for PSA, PV, and IPP, 
respectively. Using ROC curves, the areas under the curve for PSA, PV, and IPP were 0.509, 0.562 and 0.602, respectively. 
The positive predictive values of PV, PSA, and IPP were 59.7%, 55.6% and 60.2% respectively. Conclusion: PSA, PV, and 
IPP measured through transabdominal ultrasonography are noninvasive and accessible method that significantly 
correlates with BOO in BPH patients. IPP is a better predictor for BOO than PSA or PV.
Keywords: Bladder outlet obstruction, intravesical prostatic protrusion, prostate specific antigen, prostate volume, 
transabdominal ultrasound, benign prostate hyperplasia.
ABSTRAK
Tujuan: Menentukan hubungan antara intravesical prostatic protrusion (IPP), prostate specific antigen (PSA) dan volume 
prostat, dan menentukan mana yang merupakan prediktor terbaik bladder outlet obstruction (BOO) karena pembesaran 
prostat. Bahan & cara: 95 pasien laki-laki berusia > 40 tahun dengan LUTS dan BPH, antara bulan Januari sampai Juli 
2012. Mereka dievaluasi dengan digital rectal examination (DRE), International Prostate Symptoms Score (IPSS), total 
serum PSA, uroflowmetri, pengukuran post-void residu urine, IPP dan volume prostat menggunakan transabdominal 
ultrasound. Analisa statistik termasuk tes Chi-square dan tes korelasi Spearman. Kurva receiver operator characteristic 
(ROC) digunakan untuk membandingkan korelasi PSA, volume prostat dan IPP dengan BOO. Hasil: Rerata PSA secara 
statistik lebih tinggi pada pasien obstruksi (8.6 ng/mL; 0.76-130) dibandingkan pasien non-obstruksi (6.44 ng/mL; 1.0-
40.6). Rerata volume prostat secara signifikan lebih besar pada pasien obstruksi (50.33 mL ± 24.34) dibandingkan pasien 
non-obstruksi (45.39 mL ± 23.43). Rerata IPP secara signifikan lebih besar pada pasien obstruksi (7.29 ± 2.78) 
dibandingkan dengan pasien non-obstruksi (6.59 ± 2.93). Ko-efisien korelasi Spearman rho adalah 0.617, 0.721, dan 0.797 
untuk PSA, volume prostat, dan IPP. Menggunakan kurva ROC, area dibawah kurva untuk PSA, volume prostat dan IPP 
secara berurutan adalah 0.509, 0.562, dan 0.602. Nilai prediktif positif volume prostat, PSA dan IPP secara berurutan 
adalah 59.7%, 55.6% dan 60.2%. Simpulan: Pengukuran PSA, volume prostat, dan IPP melalui USG transabdominal 
adalah metode noninvasif yang dapat diakses, dan secara signifikan berkaitan dengan BOO pada pasien BPH. IPP adalah 
prediktor yang lebih baik untuk BOO daripada PSA atau volume prostat.
Kata kunci: Bladder outlet obstruction, intravesical prostatic protrusion, prostate specific antigen, volume prostat, USG 
transabdominal, benign prostate hyperplasia.
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INTRODUCTION
Benign Prostate Hyperplasia (BPH) is the 
most common benign tumor in men, and the 
incidence increases with age. The prevalence of 
histological BPH at autopsy ranged from 20% in 
men aged 41-50 years, 50% in men aged 51-60 years, 
and > 90% in men over 80 years old. Prostatic 
obstruction symptoms also appear related to age. At 
the age of 55 years, approximately 25% of men 
1reported symptoms of obstruction during urination.  
At age 75 years, 50% of men reported a reduction in 
the power of his urination. The Risk factor for BPH is 
not much understood. Some studies suggest a 
genetic predisposition, and several found its 
1,2relationship with race.
 BPH is a benign neoplasm of the prostate 
that is often found in older men. At first, if it is not 
complicated, the patient is given medical treatment; 
usually requires long-term treatment. Prostate 
volume is a major predictive factor for determining 
the progression of BPH and the response to 5á 
3reductase-inhibitor therapy.  Based on epidemiology 
studies and in patients with medical treatment, 
prostate volume increased related to symptoms, the 
development of acute urinary retention occurs, and 
4an increased incidence of prostate-related surgery.
In addition, the larger the prostate volume, 
the greater the likelihood of failure of medical 
treatment. PSA value, prostate volume and prostate 
intravesical protrusion has a linear logistic 
5relationship increases proportionally with age.  The 
6higher the age, the higher the prostate volume.  Thus, 
PSA is a predictor that can be used to assess the 
response of 5á-reductase inhibitors and progression 
of BPH, for example, if prostate volume can be 
estimated by knowing the value of PSA, it can be 
estimated that the patient has a high risk of medical 
failure because of the large volume prostate, 
especially for doctors who can not use Transrectal 
7Ultrasonography (TRUS).
OBJECTIVE
To define the relationship between 
intravesical prostatic protrusion (IPP), prostate 
specific antigen (PSA) and prostate volume (PV), 
and to determine which one of them is the best 
predictor of bladder outlet obstruction (BOO) due to 
benign prostatic enlargement.
MATERIAL & METHOD
Research data were taken from male patients 
aged 50 years or more with Lower Urinary Tract 
Symptoms (LUTS) due to benign prostatic 
enlargement suspect (BPH) in Sardjito Hospital 
from January to July 2012. A total of 114 patients 
underwent digital rectal examination, IPSS, 
uroflowmetry (Qmax), and measurement of total 
PSA value. Patients were also examined for 
transabdominal ultrasound to assess prostate 
intravesical protrusion (IPP), prostate volume (PV) 
and residual urine. Serum total PSA were divided 
into 3 groups, total PSA < 4 ng/mL, total PSA of 4-12 
ng/mL, and total PSA > 12 ng/mL. Prostate volume 
measurement by transabdominal ultrasound were 
divided into 3 groups, prostate volume < 20 mL, 
prostate volume 20-40 mL, and prostate volume
 > 40 mL.
The exclusion criteria of this study is that if 
there is a history of pelvic surgery, pelvic trauma, 
patients who underwent radiotherapy and 
neuropathic bladder. Patients with high value of total 
PSA is underwent biopsy to rule out malignancy in 
the prostate before become inclusion criteria. 
Uroflowmetry examination is conducted to measure 
the maximum urinary stream (Qmax). From the 
results of uroflowmetry, researchers divided into 2 
groups, Qmax < 10 mL/s (obstruction) and Qmax > 
10 mL/s (non-obstruction).
SPSS version 17 is used for statistical 
analysis. To test normality and demographic 
characteristics, we used one sample Kolmogorov-
Smirnov. To assess the association between variables 
Prostate intravesical protrusion (IPP), PSA and 
prostate volume (PV), we used Spearman's 
correlation coefficient with scatter plots. To assess 
the degree of strength index obstruction from an 
enlarged prostate, we used Receiver Operating 
Curves (ROC).
RESULTS 
This study consisted of 95 patients with 
clinical characteristics of patients with BPH, i.e. age, 
prostate volume (PV), prostate specific antigen 
(PSA), prostatic intravesical protrusion (IPP), 
International Prostate Symptom Score (IPSS), 
uroflowmetry (Qmax) and residual urine (PVR). IPP 
and prostate volume measured using TAUS 
(transabdominal ultrasonography) by colleagues 
from the Radiology (table 1). 
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Table 1. Demographic and clinical characteristic of BPH patients.
* Normality test with the one sample Kolmogorov -Smirnov test 
 
Demographic and clinical 
characteristic of BPH patients Value  p  
Age (years) 66.84 ± 10.09 (34; 99) 0.367* 
Prostate Volume (ml) 43.09 ± 18.96 (16.16; 128.56) 0.471* 
PSA (ng/ml) 8.43 ± 6.27 (0.76; 29.9) 0.680* 
IPP (mm) 8.65 ± 2.33 (3.1; 14.3) 0.210* 
IPSS 23.67 ± 5.1 (5; 30) 0.07 
Qmax (ml/s) 12.4 (4.8-26.3) 
PVR (ml) 52 (8-125)   
 
Table 2. Distribution of uroflowmetry results based on PV, PSA, and IPP.
Variable  Non Obstruction 
(Qmax < 10 mL/s) 
Obstruction 
(Qmax = 10 mL/s) 
Total 
(n = 95) 
PV (mL) 
     = 20  
     > 20-40  
     = 40  
PSA (ng/mL) 
     = 4 
     > 4-12 
     = 12 
IPP grade (mm) 
     = 5 
     > 5-10 
     = 10 
 
9 (56.3%) 
17 (39.5%) 
8 (22.2%) 
 
20 (51.3%) 
10 (29.4%) 
4 (18.2%) 
 
18 (60%) 
10 (29.4%) 
6 (19.4%) 
 
7 (43.7%) 
26 (60.5%) 
28 (77.8%) 
 
19 (48.7%) 
24 (70.6%) 
18 (81.8%) 
 
12 (40%) 
24 (70.6%) 
25 (80.6%) 
 
16 
43 
36 
 
39 
34 
22 
 
30 
34 
31 
Table 3. Accuracy value PV, PSA and IPP for prediction of the incidence of obstruction.
Statistics  PV PSA IPP 
Sensitivity (%)  
Specificity (%)  
Positive Predictive Value (%)  
Negative Predictive Value (%)  
51 
38 
65 
42 
30 
70 
68 
38 
46 
65 
72 
46 
On table 2, obstruction is found on 
examination of the variables uroflowmetry prostate 
volume > 40 mL of 77.8% compared with prostate 
volume < 20 mL was 43.7%. On variable PSA value, 
amounting to 48.7% of patients with PSA values ≤ 4 
with obstruction, while patients with a PSA value ≥ 
12 was 81.8% with obstruction. For IPP variables, 
obstruction score is 80.6% in patients with ≥ 10 mm 
IPP (prostate grade 3) and only 40% in patients with 
IPP ≤ 5 mm (prostate grade 1). 
Table 3 concludes descriptive statistics of 
PV, PSA and IPP. Although all three clinical 
indicators had a positive predictive value of more 
than 65%, IPP has the highest rate which is 72%. 
There is a good positive correlation between IPP, 
PSA, and PV. Coefficient of correlation between 
PSA and PV is 0.592 and between PSA and IPP is 
0.559. The correlation coefficient between the IPP 
 4
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and PV is the strongest, i.e. 0614. When all three 
indicators were correlated with BOO with scatter 
plots, correlation coefficient varied from p = 0.314-
0.507 (fig. 1-3). 
Figure 2. Scatter plot of the relationship between 
PSA with the incidence of prostate 
obstruction with obstruction events.
 
Among the three variables, IPP has the best 
correlation with BOO (fig. 3). Based on the ROC, 
IPP have the best area under the curve when 
compared to PSA and PV (fig. 4). Using the nominal 
 
Figure 3. Scatter plot of the relationship between IPP and the incidence of obstruction.
Figure 1. Scatter plot of the relationship between the 
volume of obstruction with obstruction 
events.
 
Figure 4. ROC of variable PV, serum PSA and IPP causes obstruction.
r = 0.507
5regression, IPP is the only independent variable that 
indicates the degree of obstruction (p = 0.02, 1.21 
OR, 95% CI 1.03 to 1.43). 
DISCUSSION 
Benign prostate enlargement is a major 
cause of obstruction of BOO in men aged over 50 
years who have symptoms of LUTS. Selecting 
patients for the most appropriate therapeutic strategy 
remains a challenge. Urodynamic studies are the 
gold standard in the diagnosis of BOO but the 
invasive nature limits application on a regular basis. 
Several non-invasive clinical indicator has been used 
to provide similar information so that aggressive 
therapy is performed only in patients who benefited 
from such action. IPSS is a simple tool in the 
evaluation of benign prostate enlargement, with poor 
grades indicate a need for intervention,8  but poor 
9,10correlation with BOO made it infrequent in usage.  
PVR can indicate the severity of BOO but bladder 
11dysfunction affects the value.  To further 
demonstrate contribution to the diagnosis of BOO 
anatomical components, such as parts of the prostate 
gland size (shown with PV and PSA serum) and 
configuration (indicated by IPP) should be 
considered. BOO show the existence of a physical 
obstruction in the bladder neck. It is important for 
urologists to provide aggressive therapy such as 
prostatectomy to release the obstruction. This study 
shows that PV, serum PSA and IPP correlated with 
each other. The higher the PSA, the PV will also tend 
to increase, so does the value of the IPP. This is the 
first discovery of the relationship between the three 
non-invasive clinical indicators. 
Although this study showed a good 
correlation between prostate size and configuration, 
but only in small-sized prostate gland with 
obstruction the importance of IPP is more apparent. 
This is a unique group of patients who have a small 
prostate gland with a high degree of IPP. Obstruction 
should not exist when viewed from the size criteria. 
We believe that the high rate of obstruction with 
increased IPP is caused by median lobe protrusion 
resulting in obstruction to create the effect of 'ball 
valve' during micturition. At this prospective study, 
with a single examiner, we can also show that the IPP 
correlated best with the degree of obstruction 
(BOO), when compared with PSA and PV. Other 
studies show a correlation between the size of the 
prostate with BOO and the relationship between IPP 
and BOO. However, direct comparison between the 
various aspects of the prostate gland and its 
12,13 correlation with BOO does not exist.
 Prostate volume is a predictor of progression 
of benign prostate enlargement. Men with PV ≥ 30 
mL tend to experience moderate to severe 
symptoms, reduced flow rate and acute urinary 
retention. It is also an indication for benign prostate 
14,15enlargement associated with surgery.  Serum PSA 
is often used as marker for prostate size and has been 
recognized as a good predictor for the degree of 
obstruction and incidence of benign prostate 
enlargement. Mochtar et al have shown a group of 
patients with a PSA in 18.59 amounted to estimate 
16,17closest to PV.  Patients with a PSA ≥ 1.4 ng/mL has 
increased the risk of acute urinary retention, 
increased severity of symptoms and Qmax 
decreased. Laniado et al. also showed that patients 
with high PSA associated with the degree of 
18,19obstruction is seen from urodynamic.  Although 
our prospective study have some drawbacks, the 
study population was small. Although the findings 
are statistically proven, but its significance may be 
weak. We continue to believe that this could be the 
basis for validation with a larger scale in the future. 
Long-term follow-up of 5-10 years for this group of 
patients will also give valuable clinical information 
to the progression and outcome, especially in 
patients with urodynamic proven obstruction. In the 
clinical scenario of LUTS, IPP better predicts degree 
of obstruction than PSA or PV. IPP is a more 
effective predictor of the degree of obstruction to 
identify patients at risk and lead clinician in offering 
more proactive treatment strategies.
Where researchers conducted the study, 
measurement of the degree of IPP is routinely 
performed using transabdominal ultrasound. We 
have made a grading system that has been shown to 
correlate well with the degree of obstruction (BOO). 
This can be a role model in making clinical decisions 
on the selection and operation of identifying patients 
who can follow the trial without catheter after 
micturition episodes of acute urinary retention. Our 
study shows that the configuration of the prostate 
(IPP) is more important than the size of the prostate 
(PV and PSA). IPP measurements can be easily 
obtained by abdominal ultrasound in the measure-
ment without requiring outpatient transrectal probe 
or blood sampling. Therefore, IPP measurements 
required in the evaluation of benign prostate 
enlargement and decision-making in the choice of 
20operation therapy.  
 
CONCLUSION
PSA, PV, and IPP measured through 
transabdominal ultrasonography are noninvasive 
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and accessible method that significantly correlates 
with BOO in patients with BPH. The correlation of 
IPP is much stronger than PSA and PV. It showed that 
IPP is a better predictor to indicate the degree of 
obstruction (BOO) compared with PSA or PV.
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